Demonstrated strong improvements in financial performance and business momentum.Q3 revenue of $7.42 million increased 18.7% over Q2 2024 and 111%…
DehydraTECH™ for GLP-1 being optimized for global pharmaceutical use KELOWNA, BC / ACCESSWIRE / November 7, 2024 / Lexaria Bioscience…
Revenue increased 31% for the quarter compared to same period prior yearPositive cash flows from operations of $0.35 million for…
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…
Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product…
WEDEL, Germany, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Testing new substances in animals is a regulatory cornerstone of drug development.…
MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial…
Financials for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 will be released on Thursday, November 14,…
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on…
DENVER, CO / ACCESSWIRE / November 6, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company…